91ɫ��Ƭ

From June 2025 to May 2026, 19 cryptomarkets were monitored, of which 16 remained active at the end of the reporting period.

Figure 1: Cryptomarkets monitored from June 2025 to May 2026

^{Note: There are short breaks at the end of each month to indicate the monthly interval for data collection. Extended breaks indicate periods where market crawling was not achievable or incomplete. The height of the bar is proportional to the log of the number of drug listings observed in each snapshot for each market.}

The two markets reaching more than 10,000 listings in a snapshot during this period were:

• Drughub with maximum number of listings in a snapshot of 14,386 (May 2026); and
• Torzon with maximum number of listings in a snapshot of 10,479 (May 2026).

Table 1: Characteristics of cryptomarkets monitored from June 2025 to May 2026.

^{Note: Markets are in descending order by maximum number of listings. (a) Purported reason for closure is given in brackets. (b) Maximum number of listings in a scrape was computed from the snapshots over the 12-month reporting period. (c) NA=Not Accessed. Undetected website changes resulted in an incomplete scrape in May 2026 for the Dark Matter marketplace.}

In the final month of monitoring (May 2026), 15 markets were successfully scraped. The five markets whose number of listings were above the average of 3,719 listings in May 2026 were:

• Drughub with 14,386 listings;
• Torzon with 10,479 listings;
• Nexus with 6,943 listings;
• MarsMarket with 6,888 listings; and
• Blackops with 6,281 listings.

Figure 2: Number of drug listings by cryptomarket from June 2025 to May 2026

^{Note: Markets with <1000 listings in a snapshot across the whole 12-month period (i.e., ColombiaConnection, Euphoria, CannaExpress and Atlas) were excluded to improve visibility. Complete interactive visualisation available . The markets are ordered by maximum number of listings per snapshot over the 12-month period}

Cannabis comprised the largest proportion of listings identified across the overall market over the 12-month period (25.2%). This is followed by:

• opioids (excluding heroin), with 7.3% of listings;
• benzodiazepines, with 7.2% of listings;
• MDMA, with 7.2% of listings;
• cocaine, with 6.9% of listings; and
• PIEDs/weight loss drugs, with 6.8% of listings.

Table 2: Market share (percentage of listings) by drug class from June 2025 to May 2026.

^{Note: (a) Market share is the percentage of listings out of all drug listings per snapshot across all marketplaces observed in the stated period. (b) PIEDs: . (c) These are all not in other categories of drugs. (d) These are excluding drugs already in other categories of drugs, e.g. psychostimulants and opioids which are in their specific classes of ‘other psychostimulants & nootropics’ and ‘opioids (excluding heroin)’, respectively. (e) The ‘Total’ row comprises all drug listings including those not shown in this table due to small values, i.e. alcohol, e-cigarette, inhalants, MDA, paraphernalia, PCP and tobacco, with each constituting <0.5% of the overall market share. However, GHB/GBL/1,4-BD is still shown because of recent interest in this drug in Australia.}

Heroin had the greatest rate of relative increase in market share (1.7% per month) from 2.1% in June 2025 to its highest at 2.6% in March and April 2026 before decreasing to 2.2% in May 2026. This was followed by cannabis increasing at 1.5% per month, from 24.9% to 26.2%.

Benzodiazepines showed the greatest relative decrease in market share (-4.2% per month), falling from 8.1% of all drug listings in June 2025 to a low of 4.6% in April 2026, before increasing to 8.1% again in May 2026. Within the benzodiazepine category, alprazolam, diazepam, clonazepam and zolpidem all showed significant decreases in their proportion of listings. The following drugs also decreased significantly in market share:

• GHB/GBL/1,4-BD decreasing at -3.3% per month, from 0.6% to 0.4%; and
• opioids (excluding heroin) decreasing at -2.3% per month, from 8.0% to 6.7%.

Table 3: Market share (percentage of listings) by drug class, and their average monthly percent change (AMPC in %) from June 2025 to May 2026.

^{Note: (a) Market share is the number of listings of the drug as a percentage of the number of all drug listings per snapshot across all marketplaces observed in the stated period. (b) Average monthly percent change (AMPC) in market share is the estimated relative percent change in percentage of listings of the particular drug per month. The estimates that are statistically significant at p<0.05 are marked with “*” and highlighted in bold. (c) PIEDs: . (d) These are all not in other categories of drugs. (e) These are excluding drugs already in other categories of drugs, e.g. psychostimulants and opioids which are in their specific classes of ‘other psychostimulants & nootropics’ and ‘opioids (excluding heroin)’, respectively. (f) The ‘Total’ row comprises all drug listings including those not shown in this table due to small values, i.e. alcohol, e-cigarette, inhalants, MDA, paraphernalia, PCP and tobacco, with each constituting <0.5% of the overall market share. However, GHB/GBL/1,4-BD is still shown because of recent interest in this drug in Australia.}

Man, N., Sutherland, R., Barratt, M. J., Bruno, R., Sadaphale, V., & Peacock, A. (2026). Trends in the availability and type of drugs sold on the internet via cryptomarkets, June 2025 - May 2026. Drug Trends Bulletin Series. Sydney: National Drug and Alcohol Research Centre, 91ɫ��Ƭ Sydney. Available from:

Drug Trends is supported by funding from the Australian Government Department of Health, Disability and Ageing under the Drug and Alcohol Program.

©NDARC, 91ɫ��Ƭ SYDNEY 2026 

This work is copyright. You may download, display, print and reproduce this material in unaltered form only (retaining this notice) for your personal, non-commercial use or use within your organisation. All other rights are reserved. Requests and enquiries concerning reproduction and rights should be addressed to the information manager, NDARC, 91ɫ��Ƭ Sydney, NSW 2052, Australia via drugtrends@unsw.edu.au.